{"id":164025,"date":"2023-05-16T16:23:24","date_gmt":"2023-05-16T21:23:24","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2023\/05\/novel-cancer-therapies-using-car-technology-car-applications-in-non-t-cells"},"modified":"2023-05-16T16:23:24","modified_gmt":"2023-05-16T21:23:24","slug":"novel-cancer-therapies-using-car-technology-car-applications-in-non-t-cells","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2023\/05\/novel-cancer-therapies-using-car-technology-car-applications-in-non-t-cells","title":{"rendered":"Novel Cancer Therapies Using CAR Technology: CAR Applications in Non-T Cells"},"content":{"rendered":"<p><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/novel-cancer-therapies-using-car-technology-car-applications-in-non-t-cells.jpg\"><\/a><\/p>\n<p>Chimeric antigen receptor (CAR) therapies involve the use of engineered receptors capable of redirecting immune cells to recognize and destroy cancer cells expressing a specific antigen. Currently, <a href=\"https:\/\/www.sinobiological.com\/category\/solutions\">CAR-T<\/a> cells, T cells equipped with CAR, dominate the field of CAR therapy. Since 2017, over 700 clinical trials involving CAR-T therapy have been registered and the U.S. Food and Drug Administration (FDA) has approved six CAR-T therapies for the treatment of leukemia, lymphomas, and multiple myeloma (Fig. 1) <sup>[1]<\/sup>. However, despite its clinical significance, several factors contribute to the limitations of CAR-T therapy. First, as collecting T cells is costly and time-consuming, this may not be feasible for patients already suffering from a compromised immune system. Second, CAR-T therapies mainly focus on treating hematological malignancies, having limited effectiveness in treating solid tumors. Third, CAR-T cells struggle to penetrate the tumor microenvironment (TME), which can hinder their therapeutic function. To overcome these limitations, promising CAR designs have emerged for multi-target CAR-T alongside novel therapies that utilize other immune cell types such as CAR-Natural killer (NK) and CAR-Macrophage (M) cells.<\/p>\n<p><em>Figure 1. Timeline of CAR-T FDA approvals in the US. B-ALL, B cell acute lymphoblastic leukemia; LBCL, large B cell lymphoma; MCL, mantle cell lymphoma; MM, multiple myeloma; R\/R, relapsed\/refractorySource: adapted from Maakaron, J, et al. 2022<sup>[1]<\/sup><\/em>.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Chimeric antigen receptor (CAR) therapies involve the use of engineered receptors capable of redirecting immune cells to recognize and destroy cancer cells expressing a specific antigen. Currently, CAR-T cells, T cells equipped with CAR, dominate the field of CAR therapy. Since 2017, over 700 clinical trials involving CAR-T therapy have been registered and the U.S. [\u2026]<\/p>\n","protected":false},"author":662,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11],"tags":[],"class_list":["post-164025","post","type-post","status-publish","format-standard","hentry","category-biotech-medical"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/164025","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/662"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=164025"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/164025\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=164025"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=164025"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=164025"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}